ClinicalTrials.gg
CompletedNCT01234025Updated Oct 6, 2023

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

A Phase 1/2 interventional study of ISIS EIF4E Rx and ISIS EIF4E Rx in Castrate-Resistant Prostate Cancer, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 38 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2013, 13 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing prednisone in Prostatic Neoplasms — 9 open to participants now, 17 under way, 1 of them phase 3. Prednisone · Prostatic Neoplasms.

Enrollment
23rd of 73
113 · median 57
Started
2010
with 1 other
Phase 1/2
11 of 75
2 open now
Registered
29th of 75
by date

Among the 75 studies testing prednisone in Prostatic Neoplasms, this one is the 23rd largest by enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 1/2, and was the 29th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 75 studies testing prednisone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About prednisone

Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing prednisone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.

03

Conditions studied

  • Castrate-Resistant Prostate Cancer

Browse trials for

Keywords

  • Castrate-Resistant Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written prior to Screening.
  • Age ≥ 18 years.
  • Histological or cytological diagnosis of adenocarcinoma of the prostate.
  • disease for which no curative therapy exists and for which systemic chemotherapy is indicated.
  • Progression of disease despite either medical or surgical castration. If the patient received medical androgen ablation, a castrate level of testosterone (> or = 50 ng/dL) must have been present concurrent with disease progression. Progressive disease is defined as any one of the following:

    • Rising serum PSA levels: two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart with the value of the third point being ≥ 2 ng/mL. If the third PSA level is less than the second, an additional fourth test to confirm a rising PSA (i.e., the fourth value is ≥ the second value and is ≥ 2 ng/mL) is acceptable.
    • Progressive defined as an increase in the sum of the diameters of measurable lesions over the smallest sum observed or the appearance of one or more new lesions as assessed by CT scan.
    • Bone progressions: appearance of 2 or more new lesions on bone scan or other imaging.
  • If patient did not have a surgical orchiectomy:

    • The patient must be on androgen suppression treatment (e.g. LHRH agonist), have a castrate level of testosterone (\< or = 50 ng/dL), and must be willing to continue the treatment throughout the study.
    • The patient must have discontinued treatment with anti-androgens (discontinued ≥ 4 weeks for flutamide and ≥ 6 weeks for nilutamide or bicalutamide prior to Screening) and have documented disease progression following discontinuation.
  • PSA > or = 2 ng/mL during the Screening period.
  • Performance status of 0 or 1 on the Performance Status Scale.
  • Have an estimated of at least 12 weeks.
  • Adequate organ function within 14 days prior to first study dose (ISIS EIF4E Rx or docetaxel, whichever occurs first) including the following:

    • (ANC) > or = 1.5 x 109/L.
    • count > or = 100 x 109/L.
    • Total \< or = 1.0 x (ULN).
    • (AST) \< or = 1.5 x ULN.
    • Alanine aminotransferase (ALT) \< or = 1.5 x ULN.
    • Serum creatinine \< or = 1.5 x ULN.
    • (PT) and international normalized ratio (INR) within normal limits.
    • Activated partial thromboplastin time (aPTT) within normal limits.
  • Part 1: Have had no more than 1 prior chemotherapy or biological therapy regimen (approved or experimental; all previous hormonal therapies are allowed and not counted as biological therapy for this inclusion criterion) for prostate cancer. This does not include treatments that may have been received in the or neoadjuvant setting. A regimen is defined as two or more consecutive cycles of treatment. Part 2: Have had no prior chemotherapy or biological therapy (approved or experimental; all previous hormonal therapies are allowed and not counted as biological therapy for this inclusion criterion) in any setting for prostate cancer.
  • Have discontinued all previous therapies for cancer (except treatment with LHRH analogues) as follows:

    • Part 1: cytotoxic chemotherapy must be discontinued at least 4 weeks prior to screening; Part 2: see Inclusion Criteria 11.
    • Part 1: biological treatment (other than hormonal treatments) must be discontinued for at least 6 weeks prior to screening; Part 2: see Inclusion Criteria 11.
    • Hormone therapies (e.g., abiraterone, MDV3100) must have been discontinued 4 weeks prior to screening.
    • Radiotherapy must be discontinued at least 4 weeks prior to screening, and the patient must have recovered from the acute effects of therapy.
  • Recovery from all toxicities of prior therapy to ≤ Grade 2 by , version 4.0 (Exception: any toxicity that in the view of the Investigator is not a safety risk for further therapy administration, including, but not limited to: anemia, fatigue, erectile dysfunction, hot flashes, lymphedema of an extremity, dizziness, cough, and urinary incontinence).
  • Men of must agree to use an effective form of , as determined by the Investigator, during the treatment period of the study and for 10 weeks following the last dose of study drug.
  • The patient is willing and able to comply with the study visit schedule and procedures, and geographic proximity (Investigator's discretion) that allows adequate follow-up.

Exclusion criteria

Exclusion Criteria:

  • Treatment with another drug or device within 4 weeks or biological agent within 6 weeks before Screening or 5 half-lives of study agent, whichever is longer.
  • Pre-existing peripheral neuropathy > or = , Version 4.0 (CTCAE) Grade 2.
  • Patients with treated or untreated parenchymal or . Currently active malignant epidural disease is also excluded. Previously treated epidural disease does not exclude the patient from the study. (Note: CT or MRI of brain is not needed to rule these out unless the patient has clinical symptoms suggestive of CNS metastases).
  • Have active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator).
  • Presence or history of other except non-melanoma skin cancer or solid tumors curatively treated at least 5 years previously with no subsequent evidence of recurrence.
  • Presence of an underlying disease state associated with active bleeding.
  • Ongoing therapy with oral or parenteral anticoagulants (e.g., heparin, warfarin/coumadin). Low-dose anticoagulants for maintenance of catheter patency and low dose aspirin (≤ 325 mg/day) and nonsteroidal antiinflammatory agents are not exclusionary.
  • Concurrent treatment with other anticancer drugs.
  • Inability to comply with protocol or study procedures.
  • Previous therapy with strontium or samarium.
  • Patients who have had irradiation of ≥ 25% of the bone marrow (e.g. pelvic irradiation).
  • Use of any herbal products, including saw palmetto within 1 week of screening and throughout the study.
  • Initiation of treatment with bisphosphonates, or change in dose, within 4 weeks of assignment to dosing in this study. Patients taking bisphosphonates should not have their dosing regimen altered during the study unless medically warranted.
  • Known history of , , or chronic infection.
  • Previous treatment with a therapeutic antisense oligonucleotide or siRNA.
  • Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device.
  • Have any other medical conditions that, in the opinion of the Investigator, would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1

    Drug: ISIS EIF4E Rx · Drug: Prednisone · Drug: Docetaxel

  • Experimental
    Part 1 Cohort 2

    Drug: ISIS EIF4E Rx · Drug: Prednisone · Drug: Docetaxel

  • Experimental
    Part 2 Arm A

    Drug: Prednisone · Drug: Docetaxel

  • Experimental
    Part 2 Arm B

    Drug: ISIS EIF4E Rx · Drug: Prednisone · Drug: Docetaxel

Interventions

  • DrugISIS EIF4E Rx

    800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

  • DrugISIS EIF4E Rx

    1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

  • DrugISIS EIF4E Rx

    (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.

  • 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle

  • 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: At the end of each 21 day cycle

07

Study locations

38 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • San Bernardino Urological Associates
    San Bernardino, California 92404-4816, United States
  • Fort Range Cancer Center
    Fort Collins, Colorado 80528, United States
  • Norwalk Hospital- Whittingham Cancer Center
    Norwalk, Connecticut 06850, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33805, United States
  • University of Miami, Miller School of Medicine - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Central Baptist Hospital Clinical Research Center
    Lexington, Kentucky 40503, United States
  • Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • St. Luke's - Roosevelt Hospital Center
    New York, New York 10019, United States
  • James P. Wilmont Cancer Center - University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Szent Janos Hospital and Unified Hospitals of North Buda
    Budapest, 1032, Hungary
  • Semmelweis University Faculty of Medicine
    Budapest, 1082, Hungary
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • University of Pecs, Institute of Oncology
    Pecs, 7624, Hungary
  • Fejer County St. Gyorgy Hospital, Dept of Oncology
    Szekesfehervar, 8000, Hungary
  • Ewa Pilecka Clinical Oncology Department and Outpatient Chemotherapy Unit, Bialostockie M.Sklodowska-Curie Oncology Centre in Bialystok
    Bialystok, 15-027, Poland
  • Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego, Oddzial Onkologii Klinicznej
    Grudziadz, 86-300, Poland
  • Department of Chemotherapy, Health Care Facility of the Ministry of Internal Affairs and Administration and Warminsko-Mazurskie Oncology Centre in Olsztyn
    Olsztyn, 10-228, Poland
  • Clinical Oncology Department and Day Hospitalization Unit, Independent Public Healthcare Facility T. Koszarowski Opolskie Oncology Centre in Opole
    Opole, 45-060, Poland
  • Department of Urologic Oncology, Maria Sklodowska-Curie Institute of Oncology
    Warsaw, 02-781, Poland
  • Clinical Oncology Department/Chemotherapy Department, MAGODENT Non-Public Healthcare Facility, Branch Facility No. 4
    Warsaw, 04-125, Poland
  • Fundacion de Investigacion de Diego
    San Juan, 00927, Puerto Rico
  • Alba Lulia Emergency County Hospital
    Alba Iulia, 510077, Romania
  • Dr Constantin Opris Emergency County Hospital
    Baia Mare, 430031, Romania
  • S.C. Rapid Diagnosis Polyclinic SRL
    Brasov, 500366, Romania
  • Fundeni Clinical Institute
    Bucharest, 22328, Romania
  • "Prof. Dr Th Burghele" Clinical Hospital
    Bucharest, 50659, Romania
  • SC Medisprof SRL
    Cluj-Napoca, 400058, Romania
  • S.C. Provita 2000 SRL
    Constanta, 900635, Romania
  • SC Oncolab SRL, Medical Oncology Dept
    Craiova, 200385, Romania
  • State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Clinical Oncology Center, Chemotherapy Department
    Chelyabinsk, 454087, Russian Federation
  • State Medical Institution: Kursk Regional Oncological Center, Chemotherapy Dept
    Kursk, 305035, Russian Federation
  • State Medical Institution of the City of Moscow: Municipal Clinical Hospital #57 under Moscow Department for Healthcare
    Moscow, 105077, Russian Federation
  • Non-State Medical Institution: Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC Russian Railways, Chemotherapy Dpmt
    Moscow, 129128, Russian Federation
  • Federal State Budget Institution: "Medical Radiological Research Center" under the Ministry of Health Care and Social Development of the Russian Federation
    Obninsk, 249036, Russian Federation
  • St. Petersburg State Medical Institution: St. Petersburg Municipal Oncological Center, Department of Urologic Oncology
    St Petersburg, 197022, Russian Federation
  • Russian Research Center for Radiology and Surgical Technologies
    St. Petersburg, 197758, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of May 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2010
First posted
Nov 4, 2010
Start
Nov 2010
Primary completionActual
May 2013
CompletionActual
Dec 2013
Results delay requested
Jun 21, 2018
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234025
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Nov 2010
Primary completion
May 2013
Completion
Dec 2013
Last update
Oct 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisone · Docetaxel

Start the discussion